Drugs affected by GIPR
About GIPR
GIPR is the receptor for GIP, the second incretin hormone. It is the target of the GIP arm of tirzepatide and retatrutide. The Glu354Gln variant (rs1800437) lowers GIPR function, and carriers are more likely to get moderate-to-severe nausea and vomiting on GIP-active drugs. The variant doesn't matter for GLP-1-only drugs like semaglutide.[1]
If someone is struggling with nausea on tirzepatide and carries the Gln354 variant, switching to a GLP-1-only drug often fixes it, since GIPR isn't part of the picture for those drugs.
What we test for GIPR
Gene2Rx uses definitions covering 2 named GIPR alleles, built from 1 variant in Gene2Rx definitions. Results depend on the variants available in your upload.
- Named alleles
- 2
- Defined variants
- 1
- Source
- Gene2Rx definitions
- Genome build
- GRCh38
- Normal Function 1
- Decreased Function 1
What do these allele names mean?
GIPR alleles are named by the underlying DNA variant rather than a star number. For example, c.61C>T describes a single base change at position 61 of the coding sequence.
DNA variant labels identify sequence differences. Their interpretation depends on the particular gene, the evidence, and the variants that can be assessed in your data. A DNA result does not directly measure enzyme activity.
The source of these definitions is listed above. Missing variants or incomplete coverage can leave a result indeterminate.
Medications with GIPR information
This list contains 2 medications with GIPR information from the sources shown below. Evidence and report eligibility differ by drug; each page explains its scope and limitations.
Brand products containing a GIPR-affected ingredient
These branded medications include at least one active ingredient whose metabolism or action involves GIPR. Each links to its full pharmacogenetic breakdown.
References
- PharmGKB / Stanford University. PharmGKB: The Pharmacogenomics Knowledge Base. pharmgkb.org
GIPR is one of the two genes behind GLP-1 response. Our GLP-1 genetics guide explains what each variant means for weight loss and nausea on Ozempic, Wegovy, Mounjaro, and Zepbound.
Explore GIPR in your report
Informational only, not medical advice. The presence of a GIPR pharmacogenetic guideline does not mean every patient needs to change their dose. Never start, stop, or change a medication without talking to your prescribing clinician.